RPRX
Royalty Pharma plc
Royalty Pharma plc (RPRX) has 8 SEC Form 4 filings (20 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jul 2, 2026.
The most active filer is EVP, Research & Investments Urist Marshall with 3 filings. Insiders have net sold $19.0M over the trailing 6 months.
- Industry:Medical - Pharmaceuticals
- CEO:Pablo Legorreta
- Employees:100
- HQ:New York, NY, US
- IPO:2020-06-16
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$24.2M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
| EVP & Chairman, Partnering | Sale | 130,000 | $7.3M | Jul 2 | SEC ↗ | |
| EVP, Research & Investments | Sale | 9,099 | $508K | Jul 2 | SEC ↗ | |
Hite ChristopherFirst filing | EVP & Chairman, Partnering | Sale | 150,000 | $8.2M | Jun 25 | SEC ↗ |
| EVP, Research & Investments | Sale | 9,098 | $502K | Jun 25 | SEC ↗ | |
Urist MarshallFirst filing | EVP, Research & Investments | Sale | 13,684 | $722K | May 22 | SEC ↗ |
Coyne Terrance P.First filing | EVP & CFO | Sale | 34,791 | $1.7M | Apr 30 | SEC ↗ |
Lloyd George W.First filing | EVP, Investments & CLO | Sale | 135,426 | $5.2M | Nov 21 | SEC ↗ |
Related companies
Royalty Pharma plc is in the Healthcare sector.